bluebird bio looks for new CFO
bluebird bio has commenced a search for a new CFO as Jason Cole, chief strategy and financial officer, leaves to pursue new career opportunities.
Throughout his 8.5 years at bluebird, Cole has held multiple roles including General Counsel/Chief Legal Officer (2014-2019), Chief Operating & Legal Officer (2019-2021) and Chief Business Officer (2021-2022).
“Throughout his tenure, Cole helped guide bluebird’s evolution from a small clinical stage biotech to a commercial company and has helped bluebird navigate periods of tremendous change,” notes the company.
In March this year, Cole was appointed Chief Strategy and Financial Officer at a critical juncture for the company. He led changes to stabilize the Company’s financial position and strengthen its balance sheet. Since that time, he has also served as Principal Financial Officer and Principal Accounting Officer.
Over the coming weeks, Cole will transition finance responsibilities to Katherine Breedis, an experienced business and financial executive from Danforth Advisors, who will serve as interim CFO. Meanwhile, bluebird has initiated an external search for its next CFO, with a focus on experience with commercial stage companies. Cole’s management responsibilities for strategy, external affairs and operations will be transitioned to Andrew Obenshain.
Cole’s last day with bluebird bio will be on October 14; although he will continue to consult on corporate strategy through April 2023.
